Acorda Therapeutics Names John Librie Senior Vice President, Sales and Marketing.HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ACOR ACOR Association of Cancer Online Resources ACOR American Center of Oriental Research ACOR Advanced Certificate in Operational Risk ACOR Assistant Contracting Officer Representative ACOR Actual Cost of Repair ACOR Administrative Contracting Officers Representative ) today announced that John Librie has been promoted to Senior Vice President, Sales and Marketing. Mr. Librie will continue to manage the sales and marketing efforts of Zanaflex Capsules([R]) (tizanidine hydrochloride tizanidine hydrochloride Zanaflex Pharmacologic class: Alpha-adrenergic agonist (centrally acting) Therapeutic class: Skeletal muscle relaxant Pregnancy risk category C Action), as well as oversee all pre-commercial and commercial initiatives around the Company's lead development compound, Fampridine-SR. Fampridine-SR is a sustained-release tablet being studied to evaluate its safety and efficacy in improving walking ability in people with multiple sclerosis This is a list of people with multiple sclerosis, similar to the category "People with multiple sclerosis" but with sources and explanations.: Top - 0–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z B
"John has done an outstanding job in helping to build out Acorda's overall commercial capability. Under his leadership, Acorda has developed a deeply experienced neurology sales force and a marketing team with a unique understanding of the needs of the MS community," said Ron Cohen cohen or kohen (Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. , M.D., President and Chief Executive Officer of Acorda Therapeutics. "John and his organization have a demonstrated track record of success, with sales of Zanaflex Capsules growing five-fold since the product's launch in 2005. Acorda is now well positioned to market neurological therapies that we may successfully develop, including Fampridine-SR and other earlier stage compounds in our pipeline." Mr. Librie has more than 25 years of experience in the biopharmaceutical industry and has led or been a part of fourteen product launches, including the 2006 launch of Zanaflex Capsules. Throughout his career, he has developed and expanded sales and marketing organizations to support products in specialty areas such as neurology, oncology and hormone therapy Hormone therapy Treating cancers by changing the hormone balance of the body, instead of by using cell-killing drugs. Mentioned in: Breast Cancer, Thyroid Cancer hormone therapy . As Senior Vice President, Sales and Marketing, Mr. Librie will focus on developing and executing pre-launch and launch activities for Fampridine-SR, if approved, including programs designed to increase awareness of mobility issues among people with MS, prescibers, payors and other relevant constituents. Mr. Librie joined Acorda in October 2003 as Executive Director, Marketing and Commercialization, and was promoted to Vice President, Sales and Marketing in March 2005. Prior to joining Acorda, Mr. Librie spent nine years at Genentech in various sales, sales management and marketing positions, and also served as Vice President of Sales at BTG BTG BIT (Built-In Test) Target Generator BTG Bridging the Gap BTG British Technology Group BtG Betreuungsgesetz (Germany) BTG Biomass Technology Group BV BTG Begbies Traynor Group Pharmaceuticals, a biotechnology company focusing on therapies for spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. , infectious diseases and wound care. About Fampridine-SR Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine or 4-AP). Laboratory studies have shown that fampridine can improve the communication between damaged nerves, which may result in increased neurological function. Fampridine-SR is currently being studied in Phase 3 clinical trials to evaluate its safety and efficacy to improve walking ability in people with multiple sclerosis (MS). About Acorda Therapeutics Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . The Company's marketed products include Zanaflex Capsules([R]) (tizanidine hydrochloride), a short-acting drug for the management of spasticity spasticity /spas·tic·i·ty/ (spas-tis´i-te) the state of being spastic; see spastic (2). spas·tic·i·ty n. 1. A spastic state or condition. 2. Spastic paralysis. . Acorda's lead clinical product, Fampridine-SR, is in Phase 3 clinical trials to evaluate its safety and efficacy to improve walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord spinal cord, the part of the nervous system occupying the hollow interior (vertebral canal) of the series of vertebrae that form the spinal column, technically known as the vertebral column. and brain. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of Fampridine-SR, competition, failure to protect its intellectual property or to defend against the intellectual property claims of others, the ability to obtain additional financing to support Acorda Therapeutics' operations, and unfavorable results from its preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion